Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05755685 | Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial | unknown | Phase 2 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05201612 | Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).(PEMBROLA) | unknown | Phase 2 | 40 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER |
| 1 |
| Feb 24, 2023 |
| clinicaltrials |
| NCT05732493 | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)(TORCH-C) | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 0 | Feb 17, 2023 | clinicaltrials |
| NCT05167448 | A Study of ES104 in Patients With Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 58 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05721872 | Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 38 | Nazarbayev UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05684211 | A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | unknown | Phase 2 | 84 | Shanghai Celfuture Biotech Co., Ltd.INDUSTRY | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05698082 | FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues | unknown | Phase 2 / Phase 3 | 120 | xiaoliang HuangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05659290 | Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer | unknown | Phase 2 | 40 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03883802 | Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer(NeoFox) | unknown | Phase 2 | 100 | WntResearch ABINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05640726 | The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 7, 2022 | clinicaltrials |
| NCT05634590 | The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer | unknown | Phase 2 | 68 | Fudan UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05359406 | A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis(Miracle-2) | unknown | Phase 2 | 51 | LI XIN-XIANGOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT02633098 | A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer(NeoART) | unknown | Phase 2 | 200 | St George's, University of LondonOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05575635 | Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC | unknown | Phase 2 | 40 | Henan Provincial People's HospitalOTHER | 0 | Oct 12, 2022 | clinicaltrials |
| NCT05031975 | Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy(ERASE-TMZ) | unknown | Phase 2 | 35 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524155 | Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Sep 1, 2022 | clinicaltrials |
| NCT05314101 | TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | unknown | Phase 2 | 25 | Fujian Cancer HospitalOTHER_GOV | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05511051 | A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | unknown | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04866108 | A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy | unknown | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05004831 | Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05016869 | Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 48 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04924179 | Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC | unknown | Phase 2 | 25 | Huazhong University of Science and TechnologyOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04733963 | Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | unknown | Phase 2 | 112 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05451719 | Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy | unknown | Phase 2 | 116 | Fudan UniversityOTHER | 0 | Jul 12, 2022 | clinicaltrials |
| NCT05447715 | Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer | unknown | Phase 2 | 134 | Weijian GuoOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05438108 | SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC | unknown | Phase 2 | 30 | Huazhong University of Science and TechnologyOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT03668431 | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | unknown | Phase 2 | 25 | Massachusetts General HospitalOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT02588781 | Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study | unknown | Phase 2 | 23 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03947775 | HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL | unknown | Phase 2 | 228 | University Health Network, TorontoOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT05409417 | Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05406206 | Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | unknown | Phase 2 | 27 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05402124 | The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study | unknown | Phase 2 | 100 | University of CalgaryOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05371197 | Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer | unknown | Phase 2 | 26 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05353582 | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | unknown | Phase 2 | 168 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05354817 | Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin(Re-Play) | unknown | Phase 2 | 25 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05335460 | To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer | unknown | Phase 2 | 36 | Fujian Cancer HospitalOTHER_GOV | 0 | Apr 19, 2022 | clinicaltrials |
| NCT03940131 | Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR(REPAN) | unknown | Phase 2 | 30 | King Abdullah Medical CityOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03957733 | Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients. | unknown | Phase 2 / Phase 3 | 338 | King Abdullah Medical CityOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03457896 | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | unknown | Phase 2 | 35 | NSABP Foundation IncNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05299411 | Intravenous Iron Infusion on Chemotherapy-induced Anemia | unknown | Phase 2 | 80 | Korea University Guro HospitalOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT05289726 | Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105 | unknown | Phase 2 | 152 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT05266820 | Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer | unknown | Phase 2 | 120 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04970914 | Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003(ALTER-C003) | unknown | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04167436 | Fit for Surgery. Multimodal Prehabilitation in Colorectal Cancer Patients | unknown | Phase 2 / Phase 3 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04247256 | A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI | unknown | Phase 1 / Phase 2 | 35 | Scandion Oncology A/SINDUSTRY | 3 | Mar 2, 2022 | clinicaltrials |
| NCT03748680 | IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer(IMPROVE-IT) | unknown | Phase 2 | 64 | Karen-Lise Garm SpindlerOTHER | 1 | Feb 25, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Mar 6, 2023source: clinicaltrials